Zenlabs EthicaBOM:530697 -4.96%53 EBITDA Margin % is 3.75% as of Mar. 2026, which is 15% above its 10-year median of 3.27. GuruFocus rates BOM:530697 with a GF Score™ of 53/100 and a GF Value™ of ₹29.37 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 117 Medical Distribution companies, Zenlabs Ethica ranks worse than 84.62% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Zenlabs Ethica's EBITDA for the
three
months ended in Mar. 2026 was ₹4.0 Mil. Zenlabs Ethica's Revenue for the
three
months ended in Mar. 2026 was ₹105.8 Mil. Therefore, Zenlabs Ethica's EBITDA margin for the quarter that ended in Mar. 2026 was 3.75%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Zenlabs Ethica EBITDA Margin % Related Terms
Zenlabs Ethica EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Zenlabs Ethica's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:530697 vs MCK, CAH, COR: EBITDA Margin % Comparison
For the Medical Distribution subindustry, Zenlabs Ethica's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zenlabs Ethica EBITDA Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Zenlabs Ethica's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Zenlabs Ethica's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zenlabs Ethica (BOM:530697) has a EBITDA Margin % of 3.75% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Zenlabs Ethica and its competitors. This is 15% above median its historical median of 3.27. According to the industry distribution chart, Zenlabs Ethica ranks #99 out of 117 companies in the Medical Distribution industry, placing it in the top 84.6%.
Is Zenlabs Ethica's EBITDA Margin % too high?
Zenlabs Ethica's current EBITDA Margin % of 3.75% is 15% above median its 10-year median of 3.27. The Medical Distribution industry median EBITDA Margin % is 4.28. Zenlabs Ethica's value of 3.75% is 12.4% below this industry median. Based on the distribution chart, Zenlabs Ethica ranks #99 out of 117 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Zenlabs Ethica has a GF Score™ of 53/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Zenlabs Ethica's EBITDA Margin % compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Zenlabs Ethica ranks #99 out of 117 companies for EBITDA Margin %. This places Zenlabs Ethica in the lower half of its industry. The industry median EBITDA Margin % is 4.28. Zenlabs Ethica's value of 3.75% is 12.4% below this benchmark. While the company's 10-year median is 3.27 vs. the industry median of 4.28, Zenlabs Ethica has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Distribution company?
The median EBITDA Margin % among Medical Distribution companies is 4.28, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zenlabs Ethica's current EBITDA Margin % of 3.75% is 12.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Zenlabs Ethica and its competitors. For the Medical Distribution industry, the median EBITDA Margin % is 4.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zenlabs Ethica's current EBITDA Margin % is 3.75%, which is 15% above median its own 10-year median of 3.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zenlabs Ethica stock overvalued right now?
Based on GuruFocus' analysis, Zenlabs Ethica (BOM:530697) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹29.37, compared to a current price of ₹32.60 — trading 11% above its estimated fair value. The current EBITDA Margin % is 3.75%, which is 15% above median its 10-year median of 3.27 and 12.4% below the Medical Distribution industry median of 4.28. Zenlabs Ethica's overall GF Score™ is 53/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Zenlabs Ethica (BOM:530697), the current EBITDA Margin % is 3.75% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zenlabs Ethica (BOM:530697) Overvalued in 2026?
Based on GuruFocus' analysis, Zenlabs Ethica stock appears to be overvalued.
The current stock price of ₹32.60 is trading 11% above its estimated GF Value™ of ₹29.37.
GuruFocus considers Zenlabs Ethica to be Modestly Overvalued.
Key valuation signals for BOM:530697:
EBITDA Margin %: 3.75% (15% above median its 10-year median of 3.27)
GF Value™: ₹29.37 vs. price of ₹32.60 (11% above fair value)
Industry Position: 12.4% below the Medical Distribution median (#99 of 117)
No single metric tells the full story. See the BOM:530697 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zenlabs Ethica Ltd is a pharmaceutical company engaged in the trading of pharmaceutical formulations. It manufactures and markets drugs which include Gastrointestinal disorders, anti-diabetics, anti-hypertensive drugs, anti-infective, soaps, and anti-Bacterial drugs, nutraceuticals, and others. In addition, The company offers more than 600 products across therapeutic segments.
53GF Score
Get the complete analysis for BOM:530697
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:530697 has been successfully added to your 
